The Future of Global Mental Health Management Research Report 2023: Complementing Prescription Therapies with AI/ML/VR for Better Outcomes to Become More Prominent
July 20, 2023 05:38 ET
|
Research and Markets
Dublin, July 20, 2023 (GLOBE NEWSWIRE) -- The "The Future of Mental Health Management" report has been added to ResearchAndMarkets.com's offering. This report identifies the challenges, drivers,...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
June 28, 2023 08:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Schizophrenia Drugs Market Size to Witness Healthy Valuation of US$ 12.6 Billion at 5.6% CAGR by 2032 | Market.us Report
May 25, 2023 07:54 ET
|
Market.Us
New York, May 25, 2023 (GLOBE NEWSWIRE) -- As per this latest study by Market.us, The global Schizophrenia Drugs Market was valued at US$ 7.4 Bn in 2022. It is projected to expand at a CAGR of 5.6%...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 15, 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 10, 2023 08:00 ET
|
Minerva Neurosciences, Inc
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26,...
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
May 08, 2023 08:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 01, 2023 07:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Global Precision Psychiatry Market Report to 2027 - Increasing Adoption of Inorganic Growth Strategies and Increased Demand for Genomics as Precision Psychiatry Drives Growth
March 23, 2023 05:08 ET
|
Research and Markets
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers (Genetic v/s Protein),...
Global Behavioural Health Treatment Market is expected to witness a CAGR of 2.9% during the forecast period of 2022 to 2032 | Fact.MR Report
March 21, 2023 10:00 ET
|
FACT.MR
Rockville, March 21, 2023 (GLOBE NEWSWIRE) -- The market for Behavioural Health Treatments will expand at a CAGR of 2.9%, over the forecasted time. The rise of telepsychiatry procedures in the...
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
March 08, 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...